The dog-leg: an alternative to a cross-over design for pragmatic clinical trials in relatively stable populations by Hooper, R & Bourke, L
The dog-leg: an alternative to a cross-over design for pragmatic clinical
trials in relatively stable populations.
Hooper, R; Bourke, L
 
 
 
 
 
This is a pre-copyedited, author-produced PDF of an article accepted for publication in
International Journal of Epidemiology following peer review. The version of record Hooper,
Richard, and Liam Bourke. "The dog-leg: an alternative to a cross-over design for pragmatic
clinical trials in relatively stable populations." International journal of epidemiology 43.3
(2014): 930-936. is available online at: http://dx.doi.org/10.1093/ije/dyt281
 
 
For additional information about this publication click this link.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/10811
 
 
 
Information about this research object was correct at the time of download; we occasionally
make corrections to records, please therefore check the published record when citing. For
more information contact scholarlycommunications@qmul.ac.uk
1 
 
This is a pre-copyedited, author-produced PDF of an article accepted for publication 
in International Journal of Epidemiology following peer review. The version of 
record (Hooper R, Bourke L. The dog-leg: an alternative to a cross-over design for 
pragmatic clinical trials in relatively stable populations. Int J Epidemiol 
2014;43(3):930-936) is available online at: 
http://ije.oxfordjournals.org/content/43/3/930.full.pdf+html 
 
  
2 
 
The dog-leg: an alternative to a cross-over design for pragmatic clinical trials in 
relatively stable populations 
 
Richard Hooper, 
Senior Lecturer in Medical Statistics 
 
Liam Bourke, 
Lecturer in Public Health Research 
 
 
Centre for Primary Care & Public Health, 
Queen Mary University of London 
 
 
Address for correspondence: 
 
Dr Richard Hooper, 
Centre for Primary Care & Public Health, 
Yvonne Carter Building, 
58 Turner Street, 
London E1 2AB, 
UK 
 
phone: 020 7882 7324 
fax: 020 7882 2552 
email: r.l.hooper@qmul.ac.uk 
 
 
Word count: 2891 (manuscript) + 236 (abstract) 
3 
 
Key messages 
 
We propose a novel clinical trial design called a dog-leg design which, like a cross-
over design, runs over two consecutive intervention periods. 
 
The dog-leg design does not require the effect of the experimental intervention in the 
first period to have disappeared in the second. 
 
In some realistic situations the dog-leg design is more efficient than a parallel groups 
design with a baseline assessment. 
 
The dog-leg design also requires fewer assessments in total than a parallel groups 
design where participants are only assessed once, at follow-up. 
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Summary  
 
Background 
 
A cross-over trial design is more powerful than a parallel groups design, but requires 
that treatment effects do not carry over from one period of the trial to the next. We 
focus here on interventions in chronic disease populations where the control is routine 
care: in such cases we cannot assume the intervention effect is easily washed out in 
crossing over from the experimental intervention back to the control. 
 
Methods 
 
We introduce an alternative trial design for these situations, and investigate its 
performance. One group is assessed before and after the experimental intervention, 
while two other groups provide respective, independent treatment comparisons in 
each period. We call this a dog-leg design because of the pattern of assessments in the 
three groups. The dog-leg design is reminiscent of a stepped-wedge design, but with a 
reduced schedule of assessments, and with the notable difference that not all groups 
receive the intervention. 
 
Results 
 
If the correlation between baseline and follow-up is <0.72, the dog-leg design is more 
efficient than a parallel groups design with a baseline assessment. The dog-leg design 
also requires fewer assessments in total than a parallel groups design where 
participants are only assessed once, at follow-up. 
 
Conclusions 
 
The dog-leg design is simple, and has some attractive properties. Though there is a 
risk of differential attrition in the three arms, the design’s good performance relative 
to alternatives makes it a useful addition to the methodologist’s toolkit. 
 
Keywords: clinical trial design, cross-over trials, stepped wedge, dog-leg
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Introduction 
 
Cross-over trials – clinical trials in which participants act as their own controls and 
are randomised to the order in which they get the experimental and control treatments 
– are contraindicated when the effects of treatment could carry over from one period 
of the trial to the next.1 They can work well for pharmacokinetic trials,2 but are 
problematic for interventions whose effects are intended to be durable. 
 
In this article we focus on pragmatic trials in chronic disease populations, or other 
populations with relatively stable health, and where the comparator is routine care. 
We are interested in this case in how patients would improve with the introduction of 
the new intervention. While it would be tempting to run a trial where we simply 
assess the same group of participants pre- and post-intervention, the flaw in such a 
design is that patient outcomes could change naturally over time following 
recruitment into the trial, even in a relatively stable population. A comparison group 
is needed who are assessed at the same time following recruitment but who have not 
had the intervention. 
 
The simplest approach is to randomise participants into two groups – one receiving 
the experimental intervention, the other routine care – and assess both at the end of 
the intervention period. This is the standard, parallel groups design. Such a trial can 
be done with or without a baseline assessment of outcome. The degree of advantage 
in including a baseline assessment depends on the correlation between baseline and 
follow-up assessments: the greater the correlation, the greater the advantage.3 The 
most efficient way of analysing a parallel groups design with a baseline assessment is 
with an analysis of covariance (ANCOVA), though an analysis of change scores is 
also common.4 
 
A cross-over trial, which uses participants as their own controls, achieves more power 
than a parallel groups trial, but assumes that the effect of the first period of the trial 
has disappeared by the time that the measurement of the effect in the second period is 
taken. Other designs allow for the possibility of carry-over of treatment effects. 
Balaam’s design, which consists of four arms with one for every combination of 
intervention and control in the first and second periods, is optimal under a simplifying 
assumption that the carry-over effect of having had the experimental intervention in 
the first period is the same whether you have the experimental intervention or the 
control in the second period, and similarly for the carry-over effect of the control.5 
This simplifying assumption is, however, suspect for an intervention whose effect we 
think may largely be maintained once it has been introduced. 
 
In this article we present a design which makes no assumptions about the carry-over 
effect of the experimental intervention. We are interested in the difference in outcome 
between intervention and routine care in a population previously treated with routine 
care. We will assume this difference does not depend on the duration of previous 
routine care, or equivalently that there is no carry-over effect of routine care, though 
we will allow the possibility of an overall effect of time since randomization, that is a 
natural shift in outcomes over time in the population of interest. The asymmetry in 
our assumptions about carry-over of intervention and control may be reasonable when 
the control is routine care and the population is relatively stable, but may be harder to 
justify otherwise. 
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Methods 
 
Design 
 
Figure 1 illustrates the design. Figure 1(a) shows the timing of the intervention and 
assessments post-randomisation. Routine care is assumed to be given up to the point 
that any intervention is indicated. Figure 1(b) is a schema for the schedule of 
assessments, distinguishing between assessments conducted before and after the 
intervention 
 
Participants are randomised into three arms: in the central arm (group 2) participants 
act as their own controls, being assessed both before and after the experimental 
intervention. So that effects of treatment and time since randomisation can be 
disentangled, two additional arms provide a treatment comparison in each period of 
the trial: these are not repeated in the same individuals, but rather in independent 
groups in order to avoid having to assume the intervention effect can be washed out. 
We refer to this as a dog-leg design because of the pattern formed by assessments in 
the three groups (“dog-leg” in English refers to something that is bent or crooked like 
a dog’s hind leg). 
 
Like a cross-over trial, a dog-leg trial must be run over two consecutive periods of 
intervention and follow-up. The dog-leg design is reminiscent of a stepped wedge 
design (a form of pre-post design in which the introduction of the intervention is 
staggered over a number of groups and time intervals),6 but with a reduced schedule 
of assessments, and with the notable difference that not all of the groups receive the 
intervention. We assume from the symmetry of the design that it is optimal to assign 
equal proportions of participants to groups 1 and 3, but we do not make any prior 
assumption as to what this proportion should be. 
 
[Figure 1 about here] 
 
Statistical model 
 
Suppose there are N participants in total, with the same number n in each of groups 1 
and 3. We consider a random-effects model for a Normally-distributed outcome yijk 
for individual j in group i at time k, with baseline mean , effect of time since 
randomisation , treatment effect  , and variances between and within participants 
b2 and w2, respectively. 
 
Then 
 
 y1j1 =  +  + 1j + 1j1, j = 1, …, n; 
 y2j1 =  + 2j + 2j1, j = 1, …, N-2n; 
 y2j2 =  +  +  + 2j + 2j2, j = 1, …, N–2n; 
 y3j2 =  +  + 3j + 3j2, j = 1, …, n; 
 
where 
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ij  N(0,b2), 
ijk  N(0,w2), 
 
or in vector notation 
 
,eZy 
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
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where e is multivariate Normal with mean 0 and block-diagonal variance-covariance 
matrix V. 
 
The standard error of the treatment effect could be derived using the theory of 
generalised least squares estimators, whereby the variance-covariance matrix of the 
estimator   ˆ,ˆ,ˆ  is given by  11 )(  ZVZ , but for the model specified above the 
standard error can be derived without recourse to matrix inversion by directly 
determining the minimum variance unbiased estimator (see Appendix). By comparing 
this standard error with the standard error from an ANCOVA in a parallel groups 
design (more specifically by calculating the ratio of the variances)3 we determined the 
relative efficiency of the two designs – that is, the inverse ratio of sample sizes 
required for the two designs to achieve the same statistical power. We also used the 
standard error of the treatment effect to construct sample size tables for dog-leg trials. 
 
Correlation between baseline and follow-up – a systematic review 
 
The relative advantages of different trial designs depend on the correlation between 
assessments before and after intervention in the same individual. Sample size 
calculations for trials have tended to assume this correlation is moderate.3 To provide 
information for this article on typical correlations we systematically reviewed clinical 
trials published in the Lancet or New England Journal of Medicine between 01 
January 2012 and 31 March 2013. Details of methods and results are given in the 
online supplement. 
 
Results 
 
Relative efficiency 
 
The estimate of the treatment effect from a dog-leg design is simply 
 
,2/)(ˆ 32222111 yyyy   
 
where iky  is the mean outcome in group i in period k (see Appendix). The standard 
error of this estimate depends not only on the correlation between baseline and 
follow-up, but on the proportions of participants allocated to the three arms. If the 
proportion of participants allocated to each of groups 1 and 3 is p, and the correlation 
between assessments before and after the intervention in the same individual is r, then 
the standard error is 
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where  is the standard deviation of the outcome before or after intervention, and N is 
the total sample size. Note that using our earlier notation for the relevant variance 
components,  2 = b2 + w2 and r = b2 / (b2 + w2). 
 
The standard error of the treatment effect from an ANCOVA in a parallel groups 
design with total sample size N and 1:1 allocation ratio is3 
 
.
)1(4 22
N
r
 
 
Figure 2(a) shows the relative efficiency of the dog-leg design compared with a 
parallel groups design analysed with ANCOVA, plotted against p for various values 
of r. The best choice of p depends on r, but close-to-optimal performance can be 
achieved over a wide range of r-values by choosing p=1/3, that is by allocating 
participants to arms in the ratio 1:1:1. 
 
[Figure 2 about here] 
 
Figure 2(b) shows the relative efficiency plotted against r for allocation ratios 1:1:1 
(p=1/3), 1:2:1 (p=0·25) and 2:1:2 (p=0·4). This confirms p=1/3 as a sensible choice in 
general. As long as r<0·72 the dog-leg design with allocation ratio 1:1:1 is more 
efficient than a parallel groups design analysed with ANCOVA, and may be up to 
43% more efficient (i.e. a parallel groups design analysed with ANCOVA could need 
up to 43% more participants than a dog-leg design to achieve the same statistical 
power).  
 
Compared to a parallel groups design with no baseline assessment,3 the relative 
efficiency of a 1:1:1 dog-leg design is even better, being always at least 133%. Since 
participants in a dog-leg trial each get an average of 1·33 assessments, this means the 
total number of assessments required in a dog-leg design is smaller even than the 
number required for a parallel groups design where participants are assessed only 
once, at follow-up.  
 
Sample size 
 
Using the above expression for the standard error of the treatment effect, we 
constructed a table of the sample size per group needed to achieve 80% or 90% power 
at the 5% significance level with a dog-leg design, assuming a variety of effect sizes 
and correlations between baseline and follow-up, and with a 1:1:1 allocation ratio to 
the three arms (Table 1). Sample size tables for parallel groups trials with and without 
baseline assessments are widely available.7 
 
[Table 1 about here] 
 
For example, an investigator wants to conduct a trial of a new intervention for people 
with Parkinson’s disease, and would like 80% power to detect a difference of 6 scale 
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points on a quality of life measure with a standard deviation of 15 scale points (an 
effect size of 0·4). Suppose other work with this measure suggests that the correlation 
between quality of life before and after treatment in the same individual is 0·6. A 
parallel groups design with no baseline would require 200 participants in total (100 of 
whom would receive the intervention) and 200 assessments in total.7 A parallel 
groups design with baseline assessment would require 128 participants in total (64 of 
whom would receive the intervention) and 256 assessments in total.7 From Table 1, a 
dog-leg design requires just 108 participants in total (72 of whom receive the 
intervention) and just 144 assessments in total. 
 
Correlation between baseline and follow-up 
 
Of 250 clinical trials published in the Lancet and New England Journal of Medicine 
between 01 January 2012 and 31 March 2013, 36 met the criteria specified in our 
systematic review. We were able to calculate 30 correlations from 23 of these trials 
(see online supplement): these correlations had a median of 0·71, with interquartile 
range 0·59 to 0·80. 
 
Discussion 
 
Adding further assessments 
 
As with any design, the power of the dog-leg could potentially be increased by adding 
assessments. Not all such augmentations are helpful, however. A second assessment 
in group 1 (period 2) could not be used to estimate the treatment effect because we are 
assuming nothing about the carry-over effect of the experimental intervention. A 
baseline assessment (at the time of randomisation) in group 1 is also of little help by 
itself if no other group is assessed at randomisation for comparison, since we are 
assuming a possible effect of time since randomisation. 
 
The most obvious choice for an additional assessment is in group 3, period 1 
(Figure 3). Using the generalised least squares, matrix algebra approach described in 
the Methods, we determined the standard error of the treatment effect in this 
augmented dog-leg design to be  
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where p1, p2 and p3 are the proportions of participants allocated to groups 1, 2 and 3, 
respectively. If we assume directly from the symmetry in p2 and p3 that the optimal 
allocation has p2 = p3 = p, say, then the standard error becomes 
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Figure 4 shows the relative efficiency of the augmented dog-leg design compared 
with a parallel groups design analysed with ANCOVA, for different p and r. Again a 
choice of 1:1:1 for the allocation ratio seems sensible for r>0·8, say (for larger r one 
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might as well use the ANCOVA design, which is essentially equivalent to p=0.5). 
Figure 5 shows the relative efficiency of the 1:1:1 augmented dog-leg design 
compared with the 1:1:1 dog-leg design. Interestingly, when r=0·5 there is no 
advantage to the augmented design. At other r-values there is some advantage, but for 
r<0·8 the relative efficiency never exceeds 125%, meaning that the total number of 
assessments needed for the dog-leg design is still less than the number needed for the 
augmented design. When assessments are expensive, invasive or painful, the number 
of assessments required may have at least as much practical and ethical importance as 
the number of participants. With invasive assessments, participants in group 3 in 
particular, who receive no active intervention, may question whether two assessments 
are really needed. 
 
[Figure 3 about here] 
[Figure 4 about here] 
[Figure 5 about here] 
 
Practicalities of running a dog-leg trial 
 
The dog-leg design is unconventional in having a different schedule of assessments in 
each randomised arm. Group 1 participants are not assessed in the second period of 
the trial, nor is the analysis affected by the treatment they receive in this period. The 
trial protocol should specify how participants in group 1 are to be treated in the 
second period; a choice that can be made according to ethical and scientific 
considerations. Group 3 participants, meanwhile, are not assessed until the second 
period, but this is straightforward to achieve: if the duration of each period is 3 
months, say, then a participant randomised into group 3 should have their first (and 
only) assessment scheduled at 6 months post-randomisation, just as if they were in the 
control arm of a parallel groups trial with 6-month follow-up. 
 
Data from a dog-leg trial could be analysed with standard statistical software that 
allows a mixed regression model with a random effect of participant and fixed effects 
of treatment and time since randomization. This would also enable adjustment for 
additional covariates if required. 
 
Dependence on the correlation 
 
A curious feature of the dog-leg design is that its efficiency relative to a parallel 
groups design analysed with ANCOVA first increases, and then decreases with 
increasing correlation between baseline and follow-up assessments. This is because 
for small r the ANCOVA is able to take relatively little advantage of the baseline 
assessment, while the dog-leg design is able to benefit from some participants being 
their own controls (a benefit which increases as the correlation increases). For larger r 
the ANCOVA is increasingly able to adjust for individual participant differences in 
the whole sample, out-performing the dog-leg which assesses most of its participants 
only once. 
 
Conclusions 
 
The dog-leg design requires fewer participants for the same power than a parallel 
groups design with a baseline assessment if the correlation between baseline and 
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follow-up is not too high. From our review we conclude that correlations below 0·7 
are not uncommon in studies of chronic diseases. The dog-leg design also requires 
even fewer assessments than a parallel groups design where participants are assessed 
only once, making it particularly attractive for minimising expensive or invasive 
assessments. In addition, the intervention is offered to the majority (2/3) of 
participants in a 1:1:1 dog-leg design, which may be an incentive to recruitment. 
 
On the negative side, a dog-leg trial, like a cross-over trial, must be run over two 
consecutive intervention periods, increasing the risk of attrition. Moreover there is a 
risk of differential attrition in the three arms, which differ in the timing and nature of 
contact with participants.  The dog-leg design can only be used if we are confident 
that making an assessment does not alter subsequent outcomes (some participants 
assessed in a given period have a previous assessment, and some do not). 
 
Dog-leg trials seem not to have been described previously, at least not explicitly. 
Methodological reviews of cross-over trials do not discuss them,1,8–9 indeed the dog-
leg design violates principles of balance and uniformity usually considered optimal 
for cross-over designs.10 Reviews of stepped wedge designs have asked whether 
designs with small numbers of steps should be considered methodologically 
distinct,11–12 but this seems to apply particularly to studies with two steps rather than 
three: in a recent review of 25 stepped wedge trials, nine had two steps but only one 
had three (and this was not a dog-leg design).12 Stepped wedge designs are often 
motivated by practical concerns – limited resources requiring staggering of the 
intervention; clustering of the participants; an intervention which was due to be rolled 
out anyway – whereas the dog-leg design is simply motivated by a desire to increase 
statistical power. Given its interesting properties and its simplicity, we think the dog-
leg design is a valuable addition to the methodologist’s toolkit. 
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Appendix 
 
Let iky be the mean outcome in group i at time k. If we assume a treatment effect 
estimate of the form 
 
,ˆ 32222111 ydycybya   
 
then for ˆ  to be unbiased we need 
 
a + b + c + d = 0; 
c + d = 0; 
a + c = 1. 
 
Hence the estimate has the form 
 
.)1()1(ˆ 32222111 yayayaya   
 
This has variance 
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where 
 
 2 = b2 + w2, 
r = b2 / (b2 + w2), 
p = n / N, 
 
which is minimised when a = ½ with the value 
 
.
)21(2
))1(1(2
pNp
rp


 
13 
 
References 
 
1 Mills EJ, Chan A-W, Wu P, Vail A, Guyatt GH, Altman DG. Design, analysis and 
presentation of cross-over trials. Trials 2009; 10: 27. 
2 Senn S, Ezzet F. Clinical cross-over trials in phase I. Stat Methods Med Res 1999; 
8: 263–278. 
3 Frison L, Pocock SJ. Repeated measures in clinical trials: analysis using mean 
summary statistics and its implications for design. Stat Med 1992; 11: 1685–1704. 
4 Vickers AJ, Altman DG. Analysing controlled trials with baseline and follow-up 
measurements. BMJ 2001; 323: 1123–1124. 
5 Jones B, Kenward MG. Design and analysis of cross-over trials. 2nd edn. London: 
Chapman & Hall/CRC, 2003. 
6 Hussey MA, Hughes JP. Design and analysis of stepped wedge cluster randomized 
trials. Clinical Trials 2007; 28: 182–191. 
7 Machin D, Campbell MJ, Tan SB, Tan SH. Sample size tables for clinical studies. 
3rd edn. Chichester: Wiley-Blackwell, 2009. 
8 Huitson A, Poloniecki J, Hews R, Barker N. A review of cross-over trials. J Royal 
Stat Soc D 1982; 31: 71–80. 
9 Senn S. Cross-over trials in Statistics in Medicine: the first ‘25’ years. Stat Med 
2006; 25: 3430–3442. 
10 Matthews JNS. Multi-period cross-over trials. Stat Methods Med Res 1994; 3: 383–
405. 
11 Brown CA, Lilford RJ. The stepped wedge trial design: a systematic review. BMC 
Med Res Methodology 2006; 6: 54. 
12 Mdege ND, Man M-S, Taylor CA, Torgerson DJ. Systematic review of stepped 
wedge cluster randomized trials shows that design is particularly used to evaluate 
interventions during routine implementation. J Clin Epidemiol 2011; 64: 936–948. 
14 
 
Figure legends 
 
Figure 1. Schematic representations of the dog-leg design: (a) time-line from 
randomisation in each of the three trial arms; (b) schedule of assessments (a shaded 
square indicates no assessment). 
 
Figure 2. Relative efficiency (defined as the inverse ratio of sample sizes required to 
achieve the same power) of the dog-leg design compared with an analysis of 
covariance design: (a) according to the proportion, p, allocated to each of groups 1 
and 3; (b) according to the correlation, r, between outcomes assessed in the same 
individual before and after intervention (“ratio” on the graphs refers to the allocation 
ratios to the three trial arms).  
 
Figure 3. Schematic representations of the augmented dog-leg design: (a) time-line 
from randomisation in each of the three trial arms; (b) schedule of assessments (the 
shaded square indicates no assessment). 
 
Figure 4. Relative efficiency of the augmented dog-leg design compared with an 
analysis of covariance design: (a) according to the proportion, p, allocated to each of 
groups 2 and 3; (b) according to the correlation, r, between outcomes assessed in the 
same individual in different periods. 
 
Figure 5. Relative efficiency of the 1:1:1 augmented dog-leg design compared with 
the 1:1:1 dog-leg design, according to the correlation, r, between outcomes assessed 
in the same individual in different periods. 
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Table 1. Sample size needed in each arm to achieve 80% or 90% power at the 5% 
significance level, for different assumed effect sizes (treatment difference divided by 
standard deviation of outcome), using a dog-leg design with 1:1:1 allocation to the 
three arms. 
 
Power Effect size 
Correlation between baseline and follow-up 
0·1 0·2 0·3 0·4 0·5 0·6 0·7 
                  
80% 0·1 747 708 669 630 590 551 512 
 
0·2 188 178 169 159 149 139 129 
 
0·3 85 80 76 72 67 63 58 
 
0·4 48 46 43 41 39 36 34 
 
0·5 32 30 28 27 25 24 22 
         90% 0·1 1000 947 895 842 790 737 685 
 
0·2 251 238 225 212 199 186 173 
 
0·3 113 107 101 95 89 84 78 
 
0·4 64 61 58 54 51 48 44 
 0·5 42 40 38 35 33 31 29 
 
  
 
